News for Mind Medicine (MindMed) Inc. (MMDCF)

MindMed (MNMD) has commenced dosing in its Phase 3 Emerge study for Major Depressive Disorder (MDD). The study will assess the efficacy

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NMNMD.OQ - Mind Medicine (MindMed) IncQ4 2024 Mind Medicine (MindMed) Inc Earnings CallMar 06,

The following slide deck was published by Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsStephanie Fagan - Chief Corporate...

–First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data…

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

– Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Sca…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Mind Medicine CEO Robert Barrow sells shares worth $141,957

Mind Medicine's chief legal officer sells $33,576 in stock

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a clinical-stage biopharmaceutical company developing novel product candidate

NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates…

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

Discover promising investment ideas on lesser covered stocks featuring EPR Properties, Gilead Sciences, BMW and more. Click here to read more.